Dr. Buchman assists clients with prior art research, patent preparation, patent prosecution and freedom to operate analyses. He has extensive experience in the fields of pharmaceuticals, stem cell-based therapeutics, biotechnology, immunology and diagnostic devices.
Joshua Buchman is a science advisor in the firm's Business Law Department and a member of its Intellectual Property Group. He joined Goodwin in 2012.
Prior to joining Goodwin, Dr. Buchman performed an internship at Partners HealthCare in the Division of Research Ventures and Licensing where he examined issues of commercialization and patentability related to inventions produced by Partners-affiliated research institutions. Dr. Buchman examined inventions as diverse as small molecule therapeutics for psychiatric disease treatment, novel cell culture surface materials and fabrication methods, and diagnostic devices incorporating nanotechnology. Dr. Buchman also previously performed postdoctoral research at the Dana Farber Cancer Institute where he examined the role of epigenetic regulation in cancer biology and nervous system development. Dr. Buchman’s doctoral research focused on the roles of centrosome proteins in brain development and psychiatric disease.
Dr. Buchman is a member of the Boston Patent Law Association. He has authored numerous peer-reviewed articles in Neuron, Cell, Genes and Development and Nature Reviews Neuroscience. He has also presented his research at national and international conferences.
Rutgers, The State University of New Jersey